Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $11.58 USD
Change Today 0.00 / 0.00%
Volume 834.3K
NKTR On Other Exchanges
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

nektar therapeutics (NKTR) Snapshot

Previous Close
Day High
Day Low
52 Week High
12/2/14 - $17.53
52 Week Low
04/30/15 - $9.51
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for NEKTAR THERAPEUTICS (NKTR)

nektar therapeutics (NKTR) Related Businessweek News

No Related Businessweek News Found

nektar therapeutics (NKTR) Details

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates that utilize its PEGylation and polymer conjugate technology platforms in the United States. Its product pipeline includes drug candidates in therapeutic areas comprising oncology, pain, anti-infectives, and immunology. The company offers MOVANTIK, an oral peripherally-acting mu-opioid antagonist for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain, and who have an inadequate response to laxatives. Its drug candidates in clinical development stage comprises BAX 855 that is in Phase III clinical trial for treating Hemophilia A; BAY41-6551, which is in Phase III clinical trial to treat gram-negative pneumonias; NKTR-181 that is in Phase III clinical trial for chronic pain; NKTR-171, which is in Phase I clinical trial to treat neuropathic pain; and NKTR-214 that is in research and preclinical trial stage to treat oncology, as well as MOVANTIK, which is research and preclinical stage for treating chronic pain without constipation. The company’s drug candidates in clinical development stage also include etirinotecan pegol, a topoisomerase I inhibitor that is in Phase III clinical trial for metastatic breast cancer, as well as has completed Phase II clinical trial stage for platinum-resistant/refractory ovarian cancer and second-line metastatic colorectal cancer; and in combination with 5-fluorouracil/leucovorin to treat gastrointestinal-related solid tumors, which has completed Phase I clinical trial. Nektar Therapeutics has collaboration with Baxter Healthcare; Bayer Healthcare LLC; and AstraZeneca AB. In addition, it has license, manufacturing, and supply agreements with Amgen Inc.; Allergan, Inc.; Halozyme Therapeutics, Inc.; Merck & Co., Inc.; Ophthotech Corporation; Pfizer, Inc.; F. Hoffmann-La Roche Ltd (Roche); and UCB Pharma. The company was founded in 1990 and is headquartered in San Francisco, California.

438 Employees
Last Reported Date: 02/26/15
Founded in 1990

nektar therapeutics (NKTR) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $860.0K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $542.5K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $526.1K
Chief Scientific Officer and Senior Vice Pres...
Total Annual Compensation: $477.6K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $372.7K
Compensation as of Fiscal Year 2014.

nektar therapeutics (NKTR) Key Developments

Nektar Therapeutics Provides Revenue Guidance for the Full Year of Fiscal 2015

Nektar Therapeutics provided revenue guidance for the full year of fiscal 2015. The company announced that revenue for 2015 is now expected to be between $215 million and $225 million, including $21 million of noncash royalty revenue.

Nektar Therapeutics Reports Unaudited Consolidated Earnings Results for the First Quarter Ended March 31, 2015

Nektar Therapeutics reported unaudited consolidated earnings results for the first quarter ended March 31, 2015. For the quarter, the company's total revenue was $108.8 million compared with $19.8 million a year ago. The increase in revenue in the first quarter of 2015 as compared to the first quarter of 2014 is due to the recognition of $90.0 million of the $100.0 million milestone payment from AstraZeneca following the first commercial sale of Movantik in the U.S. Income from operations was $43.0 million compared with loss from operations of $36.4 million a year ago. Income before provision for income taxes was $34.0 million compared with loss of $46.0 million a year ago. Net income was $33.8 million or $0.25 per diluted share compared with net loss of $46.2 million or $0.37 per diluted share a year ago. Net cash provided by operating activities was $63.3 million compared with net cash used in operating activities of $62.3 million a year ago. Purchases of property and equipment was $1.1 million compared with $4.5 million a year ago.

Nektar Therapeutics to Report Q1, 2015 Results on Apr 30, 2015

Nektar Therapeutics announced that they will report Q1, 2015 results at 5:00 PM, US Eastern Standard Time on Apr 30, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NKTR:US $11.58 USD 0.00

NKTR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $20.25 USD -0.17
Emergent Biosolutions Inc $31.08 USD -0.31
Ironwood Pharmaceuticals Inc $13.78 USD -0.255
Sucampo Pharmaceuticals Inc $15.93 USD -0.03
Theravance Inc $16.31 USD +0.07
View Industry Companies

Industry Analysis


Industry Average

Valuation NKTR Industry Range
Price/Earnings 57.6x
Price/Sales 5.3x
Price/Book 19.7x
Price/Cash Flow 58.3x
TEV/Sales 3.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEKTAR THERAPEUTICS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at